Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial-mesenchymal transition is critical in conquering ALK-positive lung cancer.

导出 OA

翻译打印收藏纠错

作者： Shinji,Nakamichi ^[1] ; Masahiro,Seike ^[1] ; Akihiko,Miyanaga ^[1] ; Mika,Chiba ^[1] ; Fenfei,Zou ^[1] ; Akiko,Takahashi ^[1] ; Arimi,Ishikawa ^[2] ; Shinobu,Kunugi ^[2] ; Rintaro,Noro ^[1] ; Kaoru,Kubota ^[1] ; Akihiko,Gemma ^[1]

作者单位： Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo 113-8603, Japan. ^[1] Department of Analytic Human Pathology, Graduate School of Medicine, Nippon Medical School, Tokyo 113-8603, Japan. ^[2]

关键词 ALK AXL EMT lung cancer resistance

DOI 10.18632/oncotarget.25531

PMID 29930762

发布时间 2024-11-09

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览11

Oncotarget

2018年9卷43期

27242-27255页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial-mesenchymal transition is critical in conquering ALK-positive lung cancer.

Oncotarget

相似文献

Oncotarget

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial-mesenchymal transition is critical in conquering ALK-positive lung cancer.

Oncotarget

相似文献

Oncotarget

相关期刊

检索历史清除